Solid Tumor Testing Market in the US 2018-2022

Below are some of the key findings from this solid tumor testing market in the US analysis report

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Get a FREE sample now!

Solid tumor testing market in the US overview

The growing prevalence of cancer is the primary growth factor for the solid tumor testing market in the US. Solid tumor testing evaluates the primary tumor to determine the extent of any metastasis. This testing aids the doctors to administer effective treatment options to limit the spread of cancerous cells. The growing preference for personalized medicine is encouraging the pharmaceutical companies to develop customized medicines that analyze the patient blood or tissue sample as well.

Also, the growing adoption of NGS in cancer diagnostics is the key trend driving the growth of the solid tumor testing market in the US. NGS allows multiple genomes simultaneously while allowing researchers to focus on sequenced target regions and analyze epigenetic factors. Thus, the growing prevalence of cancer coupled with the adoption of NGS in cancer diagnostics is driving the solid tumor testing market growth in the US at a CAGR of close to 11% during the forecast period.

Top solid tumor testing companies in the US covered in this report

The solid tumor testing market in the US is concentrated. The market is in the initial stage of the growth phase, and the competition is expected to become less intense by the end of the forecast period. To help clients improve their revenue shares in the market, this research report provides an analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this solid tumor testing market in the US analysis report suggests strategies companies can follow and recommends key areas they should focus on, to make the most of upcoming growth opportunities.

The report offers a detailed analysis of several leading companies, including:

• Agilent Technologies
• Becton, Dickinson and Company
• Danaher
• F. Hoffmann-La Roche
• Illumina
• Thermo Fisher Scientific

 Solid tumor testing market in the US segmentation based on technology

• Conventional testing
• Non-conventional testing

Conventional testing was the largest technology of the solid tumor testing market in the US in 2017. The market share of this segment will continue to dominate the market throughout the next five years.

Solid tumor testing market in the US segmentation based on end-user

• Hospitals
• Diagnostic laboratories
• Academic and research institutes

The hospitals segment accounted for the largest solid tumor testing market share in the US in 2017. This segment will remain the market leader for the next five years.

Key highlights of the solid tumor testing market in the US for the forecast years 2018-2022:

• CAGR of the market during the forecast period 2018-2022
• Detailed information on factors that will accelerate the growth of the solid tumor testing market in the US during the next five years
• Precise estimation of the solid tumor testing market size in the US and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• A thorough analysis of the market’s competitive landscape and detailed information on several vendors
• Comprehensive details on factors that will challenge the growth of solid tumor testing companies in the US